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Introduction {#jdi12086-sec-0005}
============

Maintaining glycemic control is the primary goal of treatment for type 2 diabetes mellitus. Several landmark studies, including the Japanese Kumamoto study[1](#jdi12086-bib-0001 jdi12086-bib-0002){ref-type="ref"} and the United Kingdom Prospective Diabetes Study[3](#jdi12086-bib-0003 jdi12086-bib-0004){ref-type="ref"}, have shown that good glycemic control using intensive insulin therapy reduces the risk of microvascular complications, and might also reduce the risk of macrovascular complications in patients with type 2 diabetes mellitus. Intensification of insulin therapy is often necessary to maintain glycemic control in patients as the disease progresses. Intensification might include switching to or adding another type of insulin and/or increasing the number of injections per day. The recent expansion of available insulin preparations allows insulin therapy to be tailored to individual patients\' clinical needs and personal preferences. In Japan, the rapid‐acting analogs, insulin lispro and insulin aspart, became available in 2001, and premixed combinations of each analog in 2003. The long‐acting preparations, insulin glargine and insulin detemir, became available in 2003 and 2007, respectively.

Insulin therapy can have both positive and negative impacts on quality of life (QOL). Insulin therapy generally provides better glycemic control and improves health‐related QOL by reducing diabetic complications[5](#jdi12086-bib-0005 jdi12086-bib-0006 jdi12086-bib-0007){ref-type="ref"}. However, insulin therapy can be inconvenient, painful and burdensome, and can restrict patients\' daily activities[8](#jdi12086-bib-0008){ref-type="ref"}. Furthermore, insulin treatment sometimes induces hypoglycemic episodes, which detract from QOL, both in terms of the actual events and the fear they cause. A number of studies have compared the effects of specific insulin types and regimens on QOL in patients with type 2 diabetes mellitus[6](#jdi12086-bib-0006 jdi12086-bib-0009 jdi12086-bib-0010 jdi12086-bib-0011 jdi12086-bib-0012 jdi12086-bib-0013 jdi12086-bib-0014 jdi12086-bib-0015 jdi12086-bib-0016){ref-type="ref"}. Most of these studies focused on insulin initiation or the comparison between insulin therapies, such as regular insulin vs rapid‐acting insulin analogs[13](#jdi12086-bib-0013 jdi12086-bib-0014 jdi12086-bib-0017 jdi12086-bib-0018){ref-type="ref"}, neutral protamine Hagedorn (NPH) vs long‐acting insulin analogs[9](#jdi12086-bib-0009 jdi12086-bib-0010 jdi12086-bib-0012){ref-type="ref"}, or multiple daily injections vs continuous subcutaneous insulin infusion (CSII)[16](#jdi12086-bib-0016){ref-type="ref"}. In contrast, few observational studies have examined the effects of changes in insulin regimen on QOL when intensifying insulin therapy in clinical practice.

The primary objective of this multicenter, observational study was to assess the changes in QOL associated with changes in insulin regimen in Japanese patients with type 2 diabetes mellitus. The secondary objectives were to assess the reasons for changing insulin regimen, the pattern of these changes and the effects on glycemic control as measured by plasma glycated hemoglobin (HbA~1c~) levels.

Materials and Methods {#jdi12086-sec-0006}
=====================

Study Design {#jdi12086-sec-0007}
------------

The INSulin‐changing study Intending to Gain patients\' insights into insulin treatment with patient‐reported Health outcomes in actual clinical Treatments (INSIGHTs) study was a 12‐week, prospective, non‐controlled observational study carried out between January and November 2010 at 68 hospital departments (including departments of endocrinology and metabolism, diabetes, and general internal medicine) in Japan. Patients with type 2 diabetes mellitus who were being treated with insulin and planned to change therapy were assessed for 12 weeks after the change in therapy (baseline). The outcomes assessed before and/or after the change in therapy included QOL, plasma levels of HbA~1c~, reasons for the change in therapy, patterns of changes in therapy, treatment adherence and satisfaction, and concomitant oral antidiabetic medication.

The study was carried out in accordance with the Declaration of Helsinki and Good Post--Marketing Study Practice (based on the International Conference for Harmonization Good Clinical Practice) in Japan[19](#jdi12086-bib-0019){ref-type="ref"}, and in accordance with the local ethical requirements at each site. Written informed consent was obtained from all patients before any study‐specific procedures were carried out. This trial was registered with [ClinicalTrials.gov](ClinicalTrials.gov) (no. NCT01055808).

Study Population {#jdi12086-sec-0008}
----------------

Patients with type 2 diabetes mellitus aged ≥20 years who planned to change one or more aspect of their insulin regimen (type of insulin, injecting device and/or number of injections per day) during the registration period were eligible to enter the study. Patients must have been receiving the same insulin regimen for at least 3 months before entering. Switching insulin preparation within the same class (e.g. insulin lispro to insulin aspart) was not considered a change in insulin regimen.

Patients were excluded from participation if they planned to discontinue insulin therapy, had used or planned to use continuous subcutaneous insulin infusion, had type 1 diabetes mellitus, had obviously poor treatment adherence (determined by the investigator and based on patient history) or were incapable of completing the study questionnaires.

Insulin Treatment Regimen During the Study {#jdi12086-sec-0009}
------------------------------------------

Patients\' individual insulin regimens during the study were determined by their treating doctors, and each insulin preparation was to be administered according to the recommended dose and frequency. The study sponsor did not provide any incentive for doctors to prescribe specific products, although individual doctors might have had personal preferences or biases. After patients changed the type of insulin, injecting device and/or number of injections per day, they could not change their insulin regimen during the study. Insulin dose adjustments, however, were allowed.

Outcome Measures {#jdi12086-sec-0010}
----------------

### Primary Outcome Measure {#jdi12086-sec-0011}

The primary outcome measure was the change from baseline in Insulin Therapy‐Related Quality of Life (ITR‐QOL) scores[17](#jdi12086-bib-0017 jdi12086-bib-0018){ref-type="ref"}. The ITR‐QOL questionnaire is a patient‐reported set of 23 questions relating to the impact of insulin therapy on aspects of daily life. Each question is rated on a five‐point scale, with higher scores indicating a better QOL. The ITR‐QOL consists of four subscales: social activities (five questions), physical functioning (four questions), daily activities (three questions) and feelings about insulin treatment (11 questions). The ITR‐QOL questionnaire was completed at baseline and at week 12 (or discontinuation).

### Secondary Outcome Measures {#jdi12086-sec-0012}

#### Change from Baseline in Plasma HbA~1c~ {#jdi12086-sec-0013}

Baseline plasma HbA~1c~ levels were determined within 4 weeks before or 5 days after baseline. End‐of‐study plasma HbA~1c~ levels were determined within 2 weeks of week 12 (i.e. between week 10 and week 14) or discontinuation. Plasma HbA~1c~ levels were measured at local laboratories using standard methods, and are expressed as National Glycohemoglobin Standardization Program equivalent values (i.e. the Japan Diabetes Society HbA~1c~ value +0.4%[20](#jdi12086-bib-0020 jdi12086-bib-0021){ref-type="ref"}).

#### Reasons for Change in Insulin Regimen {#jdi12086-sec-0014}

At baseline, both patients and doctors chose one or more from a list of reasons (Table [2](#jdi12086-tbl-0002){ref-type="table-wrap"}) for the change (including 'Other').

#### Pattern of Changes in Insulin Regimen {#jdi12086-sec-0015}

The details of each patient\'s insulin regimen were recorded before the regimen was changed, at baseline and at week 12 (or discontinuation). These details included the category of insulin: (i) rapid‐acting (rapid‐ or ultra‐rapid‐acting); (ii) biphasic (biphasic/premixed); (iii) long‐acting (intermediate‐ or long‐acting/basal); (iv) the type of insulin preparation (e.g. human insulin or insulin analog); (v) the number of injections per day; (vi) the time(s) of injection (before breakfast, before lunch, before dinner, bedtime); (vii) the type of injecting device (disposable, cartridge, syringe); and (viii) the total insulin dose per day.

#### Treatment Adherence {#jdi12086-sec-0016}

Patients completed a treatment adherence questionnaire, in which they reported the extent of adherence (always, often, usually, occasionally, not at all) for each injection time, at baseline and at week 12 (or discontinuation).

#### Concomitant Oral Antidiabetic Medication {#jdi12086-sec-0017}

All concomitant oral antidiabetic medications were recorded at baseline and at week 12 (or discontinuation).

#### Change From Baseline in Diabetes Treatment Satisfaction Questionnaire Score {#jdi12086-sec-0018}

The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a patient‐reported assessment of treatment satisfaction (six questions) and perceived frequency of severe hypoglycemia and hyperglycemia (two questions)[22](#jdi12086-bib-0022){ref-type="ref"}. Each question is rated on a six‐point scale, with higher scores indicating either greater treatment satisfaction or greater perceived frequency of hypoglycemic or hyperglycemic events. Patients completed a Japanese version of the DTSQ[23](#jdi12086-bib-0023){ref-type="ref"} at baseline and at week 12 (or discontinuation).

### Questionnaire Procedures {#jdi12086-sec-0019}

Patients normally completed all questionnaires at the study site, but not in the presence of their doctors. All completed questionnaires (both patient and doctor) were sealed and submitted according to each institution\'s procedures.

Statistical Analysis {#jdi12086-sec-0020}
--------------------

The standard deviation (SD) of the change in the total ITR‐QOL score was assumed to be 12.0, based on previous results[17](#jdi12086-bib-0017){ref-type="ref"}. To estimate the change from baseline in the ITR‐QOL total score with sufficient precision (95% confidence interval for the estimated mean change with a width of 2.0), 554 patients were required. Allowing for 20% dropout, the study aimed to include approximately 700 patients.

Summary statistics (mean, SD) were calculated for all continuous variables (e.g. age, weight, ITR‐QOL scores, HbA~1c~ levels). A one‐sample *t*‐test was used to compare baseline and week 12 values within patient subgroups, and a two‐sample *t*‐test was used to compare changes from baseline between patient subgroups. A multiple linear regression model was used to assess the relationship between independent variables (age, sex, body mass index, baseline HbA~1c~ level, duration of diabetes, number of insulin injections, type of insulin and device) and the change from baseline in plasma HbA~1c~ level. A backward, step‐down method was used to further assess variables with *P* \< 0.05 in the full regression model. Missing data were not imputed. All statistical analyses were carried out using SAS^®^ version 9.1.3 (SAS, Cary, NC, USA), and *P*‐values ≤0.05 were considered significant.

Results {#jdi12086-sec-0021}
=======

Patient Disposition and Baseline Characteristics {#jdi12086-sec-0022}
------------------------------------------------

A total of 674 patients were registered, of whom 625 were evaluated (Figure [1](#jdi12086-fig-0001){ref-type="fig"}). The most common reason for exclusion of registered patients from evaluation was protocol violation. The most common reason for discontinuation during the study was a subsequent change in insulin regimen.

![Patient disposition, including number of patients with end‐of‐study primary outcome (ITR‐QOL) data. \*Includes two patients with both a change in insulin regimen plus another reason for discontinuation.](jdi-4-560-g1){#jdi12086-fig-0001}

The baseline characteristics of the patients were typical of Japanese patients with type 2 diabetes mellitus (Table [1](#jdi12086-tbl-0001){ref-type="table-wrap"})[24](#jdi12086-bib-0024){ref-type="ref"}. Among the evaluated patients, the mean age was 63.3 years, the mean BMI was 24.52 kg/m^2^ and there were more men (54.2%) than women (45.8%). Most patients had a prolonged history of diabetes and insulin treatment (mean durations of 16.15 and 7.17 years, respectively). Approximately 60% of patients were taking oral antidiabetic medications. Most patients (86.4%) had one or more complications of diabetes.

###### Patient characteristics at baseline

  Variables                                                  Value *n* = 625
  ---------------------------------------------------------- -----------------
  Mean age, years (SD)                                       63.3 (12.0)
  Sex, *n* (%)                                               
  Men                                                        339 (54.2%)
  Women                                                      286 (45.8%)
  Mean height, cm (SD)                                       160.73 (9.47)
  Mean weight, kg (SD)                                       63.59 (13.82)
  Mean body mass index, kg/m^2^ (SD)                         24.52 (4.32)
  Mean duration of diabetes, years (SD)                      16.15 (8.91)
  Mean duration of insulin treatment, years (SD)             7.17 (5.53)
  Concomitant oral antidiabetic medication, *n* (%)          
  None                                                       259 (41.4%)
  At least one type[a](#jdi12086-note-0001){ref-type="fn"}   366 (58.6%)
  Biguanide                                                  189 (30.2%)
  α‐Glucoside inhibitor                                      161 (25.8%)
  Sulfonylurea                                               157 (25.1%)
  Thiazolidinedione                                          71 (11.4%)
  Glinide                                                    18 (2.9%)
  Complications of diabetes, *n* (%)                         
  Present                                                    540 (86.4%)
  Absent                                                     84 (13.4%)
  Unknown                                                    1 (0.2%)
  Type of complication, *n* (%)                              
  Hypertension                                               334 (53.4%)
  Dyslipidemia                                               320 (51.2%)
  Diabetic retinopathy                                       287 (45.9%)
  Diabetic neuropathy                                        238 (38.1%)
  Diabetic nephropathy                                       220 (35.2%)

Some patients used more than one oral antidiabetic medication. SD, standard deviation.

John Wiley & Sons, Ltd

Changes in Insulin Therapy {#jdi12086-sec-0023}
--------------------------

Most (521 of 625; 83.4%) patients changed the type of insulin as part of the change in insulin regimen (Figure [2](#jdi12086-fig-0002){ref-type="fig"}). Approximately 20% (126 of 625; 20.2%) of patients changed the type of device and approximately 30% (183 of 625; 29.3%) of patients changed the number of injections. Among patients who changed the number of injections, most (149 of 183; 81.4%) also changed the type of insulin.

![Overlap of changes in insulin type, device and number of injections among patients with type 2 diabetes mellitus (*n* = 625).](jdi-4-560-g2){#jdi12086-fig-0002}

Overall, the most common reason for changing insulin regimen was 'poorly controlled glycemia' (Table [2](#jdi12086-tbl-0002){ref-type="table-wrap"}). This was the most common doctor‐reported reason and the second most common patient‐reported reason. Among patients, the most common reason for regimen change was 'recommendation from the doctor', which might have been related to poorly controlled glycemia, although this cannot be determined from the questionnaires. 'Change of insulin preparation(s)' was the second most common doctor‐reported reason and the third most common patient‐reported reason.

###### Reasons for change in insulin therapy

  Reason                                                                  Doctor‐reported *n* (%) *n* = 625   Patient‐reported *n* (%) *n* = 625   Agreement rate
  ----------------------------------------------------------------------- ----------------------------------- ------------------------------------ ----------------
  Poorly controlled glycemia                                              388 (62.1%)                         313 (50.1%)                          0.75
  Change of insulin preparation(s)                                        179 (28.6%)                         106 (17.0%)                          0.70
  Dissatisfaction with device                                             69 (11.0%)                          56 (9.0%)                            0.85
  Concern about hypoglycemia                                              53 (8.5%)                           62 (9.9%)                            0.86
  Dissatisfaction with number of doses                                    32 (5.1%)                           31 (5.0%)                            0.94
  User‐friendliness                                                       20 (3.2%)                           22 (3.5%)                            0.95
  Patient request (for doctors) or doctor recommendation (for patients)   17 (2.7%)                           407 (65.1%)                          0.32
  Concern about safety other than hypoglycemia                            3 (0.5%)                            17 (2.7%)                            0.97
  Other                                                                   83 (13.3%)                          54 (8.6%)                            0.84
  No answer                                                               2 (0.3%)                            31 (5.0%)                            NA

NA, not applicable.

John Wiley & Sons, Ltd

The three categories of insulin type were used with similar prevalence both before and after the change in insulin therapy (Table [3](#jdi12086-tbl-0003){ref-type="table-wrap"}). Common timings of injections were before breakfast, lunch and dinner for rapid‐acting insulin, and before breakfast and dinner for biphasic insulin. Regarding long‐acting insulin, the most common timing of injection was bedtime. Biphasic insulin only (i.e. without an additional insulin type) was the most commonly used insulin both before and after the change in regimen (Table [4](#jdi12086-tbl-0004){ref-type="table-wrap"}). Changes in insulin regimen were associated with a decrease in the proportion of patients using one type of insulin (from 64.5 to 55.4%) and an increase in the proportion of patients using two types of insulin (from 34.4 to 43.0%; Table [4](#jdi12086-tbl-0004){ref-type="table-wrap"}).

###### Changes in insulin type and injection time before and during the 12‐week study

  Category of insulin Type of insulin   Injection time     Before change *n* (%) *n* = 625   After change[a](#jdi12086-note-0003){ref-type="fn"} *n* (%) *n* = 625   Week 12 *n* (%) *n* = 622
  ------------------------------------- ------------------ --------------------------------- ----------------------------------------------------------------------- ---------------------------
  Rapid‐acting                          Any                255 (40.8%)                       268 (42.9%)                                                             265 (42.6%)
  Rapid‐acting insulin                  Before breakfast   228 (36.5%)                       235 (37.6%)                                                             233 (37.5%)
  Ultra‐rapid‐acting analog             Before lunch       229 (36.6%)                       235 (37.6%)                                                             232 (37.3%)
  Before dinner                         185 (29.6%)        205 (32.8%)                       203 (32.6%)                                                             
  Bedtime                               0 (0.0%)           0 (0.0%)                          0 (0.0%)                                                                
  Biphasic                              Any                321 (51.4%)                       364 (58.2%)                                                             363 (58.4%)
  Biphasic insulin                      Before breakfast   268 (42.9%)                       314 (50.2%)                                                             313 (50.3%)
  Biphasic analog                       Before lunch       63 (10.1%)                        120 (19.2%)                                                             121 (19.5%)
  Before dinner                         301 (48.2%)        334 (53.4%)                       332 (53.4%)                                                             
  Bedtime                               2 (0.3%)           1 (0.2%)                          1 (0.2%)                                                                
  Long‐acting                           Any                278 (44.5%)                       282 (45.1%)                                                             277 (44.5%)
  Intermediate‐acting insulin           Before breakfast   118 (18.9%)                       109 (17.4%)                                                             107 (17.2%)
  Intermediate‐acting analog            Before lunch       5 (0.8%)                          2 (0.3%)                                                                3 (0.5%)
  Long‐acting analog                    Before dinner      97 (15.5%)                        95 (15.2%)                                                              92 (14.8%)
  Bedtime                               137 (21.9%)        146 (23.4%)                       143 (23.0%)                                                             

Immediately after change in insulin therapy (i.e. baseline).

John Wiley & Sons, Ltd

###### Changes in insulin type combinations before and during the 12‐week study

  Combination                             Before change *n* (%) *n* = 625   After change[a](#jdi12086-note-0004){ref-type="fn"} *n* (%) *n* = 625   Week 12 *n* (%) *n* = 622
  --------------------------------------- --------------------------------- ----------------------------------------------------------------------- ---------------------------
  No insulin used                         0 (0.0%)                          0 (0.0%)                                                                2 (0.3%)
  Rapid‐acting only                       49 (7.8%)                         21 (3.4%)                                                               21 (3.4%)
  Biphasic only                           235 (37.6%)                       271 (43.4%)                                                             271 (43.6%)
  Long‐acting only                        119 (19.0%)                       54 (8.6%)                                                               53 (8.5%)
  Rapid‐acting + biphasic                 63 (10.1%)                        51 (8.2%)                                                               51 (8.2%)
  Rapid‐acting+ long‐acting               136 (21.8%)                       186 (29.8%)                                                             183 (29.4%)
  Biphasic + long‐acting                  16 (2.6%)                         32 (5.1%)                                                               31 (5.0%)
  Rapid‐acting + biphasic + long‐acting   7 (1.1%)                          10 (1.6%)                                                               10 (1.6%)

Immediately after change in insulin therapy (i.e. baseline).

John Wiley & Sons, Ltd

The proportion of patients using each type of injection device did not change substantially after the change in insulin regimen. Disposable devices were the most common devices used both before (471 patients; 75.4%) and after (486 patients; 77.8%) the change in regimen. Cartridges (before change: 127 patients, 20.3%; after change: 94 patients, 15.0%) were also used. A small number of patients used both disposable devices and cartridges (before change: 24 patients, 3.8%; after change: 43 patients, 6.9%). A few patients used syringes (before change: three patients, 0.5%; after change: two patients, 0.3%).

Most patients injected insulin two or three times a day both before and after the change in insulin regimen (Figure [3](#jdi12086-fig-0003){ref-type="fig"}). However, the proportion of patients who injected insulin three or four times a day increased after the change in regimen.

![Number of insulin injections per day among patients with type 2 diabetes mellitus before (white columns) and after (black columns) changing insulin regimen (*n* = 625).](jdi-4-560-g3){#jdi12086-fig-0003}

Quality of Life {#jdi12086-sec-0024}
---------------

In the whole population, QOL did not worsen during the 12‐week study. There was no statistically significant change in the ITR‐QOL total score from baseline to week 12 (Table [5](#jdi12086-tbl-0005){ref-type="table-wrap"}). There was a small, but statistically significant, increase only in the daily activities subscale score.

###### Insulin therapy‐related quality of life subscale and total scores during the 12‐week study

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Subscale (range of possible scores)               Score Mean (SD)   *P*‐value[a](#jdi12086-note-0005){ref-type="fn"}                   
  ------------------------------------------------- ----------------- -------------------------------------------------- --------------- -------
  Social activities (5--25 points)                  22.0 (3.7)\       22.2 (3.7)\                                        0.12 (2.99)\    0.341
                                                    \                 \                                                  \               
                                                    *n* = 609         *n* = 583                                          *n *= 567       

  Physical functioning (4--20 points)               17.3 (2.5)\       17.4 (2.6)\                                        0.04 (2.17)\    0.672
                                                    \                 \                                                  \               
                                                    *n* = 612         *n* = 583                                          *n* = 571       

  Daily activities (3--15 points)                   12.7 (2.3)\       12.9 (2.3)\                                        0.18 (2.08)\    0.038
                                                    \                 \                                                  \               
                                                    *n* = 614         *n* = 578                                          *n* = 568       

  Feeling about insulin treatment (11--55 points)   44.6 (9.0)\       45.1 (9.3)\                                        0.54 (7.06)\    0.073
                                                    \                 \                                                  \               
                                                    *n* = 593         *n* = 591                                          *n* = 562       

  Total score (23--115 points)                      97.0 (15.2)\      97.8 (15.6)\                                       0.86 (11.25)\   0.082
                                                    \                 \                                                  \               
                                                    *n* = 575         *n* = 560                                          *n* = 518       
  ----------------------------------------------------------------------------------------------------------------------------------------------

One‐sample *t*‐test. SD, standard deviation.

John Wiley & Sons, Ltd

Ad hoc analysis by type of regimen changes (type of insulin, injection device and/or number of injections) in the ITR‐QOL total score showed no statistically significant differences between subgroups in each type of change (Table [6](#jdi12086-tbl-0006){ref-type="table-wrap"}). Statistically greater increases in the ITR‐QOL total score from baseline to week 12 were observed in the subgroups of patients who changed type of insulin, who did not change type of injection device and who did not change the number of injections, whereas the ITR‐QOL total score did not change in the subgroups of patients who did not change type of insulin, who changed type of injection device and who changed the number of injections.

###### Subgroup analysis of changes in the Insulin Therapy‐Related Quality of Life total score during the 12‐week study

  Insulin therapy change     ITR‐QOL total score Mean (SD)   Within group *P*‐value[\*](#jdi12086-note-0006){ref-type="fn"}   Difference between groups[†](#jdi12086-note-0006){ref-type="fn"} (95% CI)   Between group *P*‐value[§](#jdi12086-note-0006){ref-type="fn"}                         
  -------------------------- ------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------- --------------------- -------
  Type of insulin                                                                                                                                                                                                                                                                                
  Not changed                97.3 (13.5) *n* = 135           97.3 (14.8) *n* = 125                                            −0.18 (10.30) *n* = 123                                                     0.848                                                                                  
  Changed                    96.9 (15.7) *n* = 440           97.9 (15.8) *n* = 435                                            1.18 (11.52) *n* = 395                                                      0.042                                                                                  
                                                                                                                                                                                                                                                                           1.36 (−0.92, 3.64)    0.241
  Type of injection device                                                                                                                                                                                                                                                                       
  Not changed                97.1 (15.4) *n* = 457           97.9 (15.9) *n* = 446                                            1.19 (11.37) *n* = 411                                                      0.034                                                                                  
  Changed                    96.5 (14.5) *n* = 118           97.2 (14.6) *n* = 114                                            −0.42 (10.70) *n* = 107                                                     0.685                                                                                  
                                                                                                                                                                                                                                                                           −1.62 (−4.01, 0.78)   0.186
  No. injections                                                                                                                                                                                                                                                                                 
  Not changed                96.7 (15.5) *n* = 411           98.1 (15.6) *n* = 398                                            1.25 (10.77) *n* = 370                                                      0.027                                                                                  
  Changed                    97.7 (14.6) *n* = 164           97.0 (15.6) *n* = 162                                            −0.10 (12.35) *n* = 148                                                     0.921                                                                                  
                                                                                                                                                                                                                                                                           −1.35 (−3.50, 0.80)   0.218

\*One‐sample *t*‐test. †Mean change from baseline in the 'Changed' group minus mean change from baseline in the 'Not changed' group. §Two‐sample *t*‐test. CI, confidence interval; ITR‐QOL, Insulin Therapy‐Related Quality of Life; SD, standard deviation.

John Wiley & Sons, Ltd

Multiple linear regression analysis was also carried out, but none of the following variables were significantly associated with the change in the ITR‐QOL total score: age, sex, BMI, duration of diabetes, baseline HbA~1c~ level, the number of injections per day before regimen change, type of insulin before regimen change and device before regimen change (data not shown).

The 'perceived frequency of hyperglycemia' DTSQ subscale score (mean ± SD) decreased significantly at 12 weeks from baseline (baseline: 3.4 ± 1.6; week 12: 3.0 ± 1.7; *n* = 573; *P* ≤ 0.001), in accordance with improved glycemic control. The 'treatment satisfaction' DTSQ subscale mean improved numerically, but was not statistically significant at week 12 (baseline: 24.8 ± 6.4; week 12: 25.4 ± 6.4; *n* = 552). There was little change in the 'perceived frequency of hypoglycemia' (baseline: 1.7 ± 1.5; week 12: 1.8 ± 1.5; *n* = 571; *P* = 0.106) DTSQ subscale score.

Plasma HbA~1c~ Levels {#jdi12086-sec-0025}
---------------------

Plasma HbA~1c~ levels decreased significantly (mean change =−0.37 ± 0.97%, *n* = 606, *P* \< 0.001) from 8.21 ± 1.47% (*n* = 618) at baseline to 7.85 ± 1.31% (*n* = 610) at week 12.

Subgroup analysis based on the type of changes in plasma HbA~1c~ levels showed statistically significantly greater decreases in plasma HbA~1c~ levels in patients who changed the type of insulin or the number of injections compared with patients who did not make these changes (Table [7](#jdi12086-tbl-0007){ref-type="table-wrap"}).

###### Subgroup analysis of changes in plasma glycated hemoglobin levels during the 12‐week study

  Insulin therapy change     HbA~1c~ Mean% (SD)        Within group *P*‐value[\*](#jdi12086-note-0007){ref-type="fn"}   Difference between groups[†](#jdi12086-note-0007){ref-type="fn"} (95% CI)   Between group *P*‐value[§](#jdi12086-note-0007){ref-type="fn"}                          
  -------------------------- ------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------- ---------------------- ---------
  Type of insulin                                                                                                                                                                                                                                                                           
  Not changed                8.11 (1.56) *n *=* *135   7.87 (1.35) *n *=* *132                                          −0.21 (0.80) *n *=* *132                                                    0.003                                                                                   
  Changed                    8.24 (1.44) *n *=* *483   7.85 (1.29) *n *=* *478                                          −0.41 (1.01) *n *=* *474                                                    \<0.001                                                                                 
                                                                                                                                                                                                                                                                     −0.20 (−0.39, −0.01)   0.035
  Type of injection device                                                                                                                                                                                                                                                                  
  Not changed                8.24 (1.44) *n *=* *493   7.87 (1.33) *n *=* *487                                          −0.38 (1.00) *n *=* *483                                                    \<0.001                                                                                 
  Changed                    8.11 (1.55) *n *=* *125   7.80 (1.21) *n *=* *123                                          −0.31 (0.86) *n *=* *123                                                    \<0.001                                                                                 
                                                                                                                                                                                                                                                                     0.07 (−0.12, 0.26)     0.478
  No. injections                                                                                                                                                                                                                                                                            
  Not changed                8.01 (1.35) *n *=* *438   7.77 (1.33) *n *=* *431                                          −0.25 (0.84) *n *=* *429                                                    \<0.001                                                                                 
  Changed                    8.72 (1.62) *n *=* *180   8.06 (1.22) *n *=* *179                                          −0.66 (1.18) *n *=* *177                                                    \<0.001                                                                                 
                                                                                                                                                                                                                                                                     −0.42 (−0.58, −0.25)   \<0.001

\*One‐sample *t*‐test. †Mean change from baseline in the 'Changed' group minus mean change from baseline in the 'Not changed' group.§Two‐sample *t*‐test. CI, confidence interval; HbA~1c~, glycated hemoglobin; SD, standard deviation.
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Multiple linear regression analysis identified a statistically significant association between the change in plasma HbA~1c~ level and the baseline HbA~1c~ level, baseline BMI, and the number of insulin injections before the regimen change (Table [8](#jdi12086-tbl-0008){ref-type="table-wrap"}). Independent variables including age, sex, duration of diabetes, type of insulin before regimen change and device before regimen change were not significant. The decrease in plasma HbA~1c~ level was greater in patients with higher baseline HbA~1c~ levels compared with patients with lower HbA~1c~ levels, in patients with BMI \<25 kg/m^2^ compared with patients with BMI ≥25 kg/m^2^ and in patients with two or more insulin injections per day before the change in regimen compared with patients with one injection before the change. These associations were confirmed by backward, step‐down regression analysis. However, these variables only accounted for 27% of the variance in the change in plasma HbA~1c~ levels.

###### Multiple linear regression analysis of change from baseline in plasma glycated hemoglobin levels during the 12‐week study

  Variables                                      Full regression model   Step‐down regression model                          
  ---------------------------------------------- ----------------------- ---------------------------- ---------------------- ---------
  Intercept                                      1.63 (1.09, 2.17)       \<0.001                      1.85 (1.42, 2.28)      \<0.001
  Age                                                                                                                        
  \<65 years                                     Reference               --                                                  
  ≥65 years                                      0.02 (−0.13, 0.16)      0.815                                               
  Sex                                                                                                                        
  Male                                           Reference               --                                                  
  Female                                         0.07 (−0.07, 0.21)      0.310                                               
  BMI                                                                    0.051                                               0.022
  \<25 kg/m^2^                                   Reference               --                           Reference              --
  ≥25 kg/m^2^                                    0.18 (0.03, 0.32)       0.016                        0.20 (0.06, 0.34)      0.006
  Unknown                                        0.20 (−0.64, 1.05)      0.640                        0.19 (−0.64, 1.02)     0.653
  Duration of diabetes                                                   0.728                                               
  \<15 years                                     Reference               --                                                  
  ≥15 years                                      −0.06 (−0.21, 0.09)     0.449                                               
  Unknown                                        −0.07 (−0.34, 0.21)     0.634                                               
  Baseline plasma HbA1c level                    −0.33 (−0.38, −0.28)    \<0.001                      −0.33 (−0.37, −0.28)   \<0.001
  No. injections per day before regimen change                           0.069                                               0.038
  1                                              Reference               --                           Reference              --
  2                                              0.23 (−0.02, 0.49)      0.073                        0.25 (0.03, 0.47)      0.023
  3                                              0.41 (0.09, 0.73)       0.011                        0.33 (0.10, 0.55)      0.004
  4                                              0.51 (0.09, 0.93)       0.019                        0.27 (0.02, 0.53)      0.035
  Type of insulin before regimen change                                  0.368                                               
  Rapid‐acting only                              Reference               --                                                  
  Biphasic only                                  0.30 (0.01, 0.59)       0.044                                               
  Long‐acting only                               0.24 (−0.12, 0.59)      0.188                                               
  Rapid‐acting + biphasic                        0.17 (−0.15, 0.50)      0.292                                               
  Rapid‐acting + long‐acting                     −0.02 (−0.38, 0.33)     0.896                                               
  Biphasic + long‐acting                         0.17 (−0.34, 0.67)      0.519                                               
  Rapid‐acting + biphasic + long‐acting          0.05 (−0.65, 0.75)      0.887                                               
  Device before change                                                   0.130                                               
  Disposable                                     Reference               --                                                  
  Cartridge                                      0.01 (−0.17, 0.19)      0.907                                               
  Syringe                                        −0.88 (−1.85, 0.09)     0.076                                               
  Disposable + cartridge                         0.31 (−0.08, 0.69)      0.115                                               
  Coefficient of determination (*R*^2^)          0.270                                                0.253                  

BMI, body mass index; CL, confidence limit; HbA~1c~, glycated hemoglobin.
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There was a small, but statistically significant, increase in the total daily dose of insulin (baseline: 30.7 ± 21.8 IU; week 12: 31.5 ± 20.1 IU; change = 0.8 ± 9.0 IU; *n* = 620; *P* = 0.023) during the study; however, the increase was not considered clinically significant.

Patient‐Reported Treatment Adherence {#jdi12086-sec-0026}
------------------------------------

The change in insulin regimen was not associated with any apparent change in patient‐reported treatment adherence. Most patients reported adhering to treatment always or often at all injection times both before and after the change in insulin regimen.

Concomitant Oral Antidiabetic Medication {#jdi12086-sec-0027}
----------------------------------------

The proportion of patients who were taking concomitant oral antidiabetic medication decreased slightly after the change in insulin regimen (before change: *n* = 366; 58.6%; after change: *n* = 347; 55.5%) and was maintained at week 12 (*n* = 348; 55.7%).

Discussion {#jdi12086-sec-0028}
==========

The psychological barriers to initiating or intensifying insulin therapy are well known and include a fear of reduced QOL. Although patients are generally more receptive to changing insulin regimen than to initiating insulin, some psychological barriers still exist, including perceived effects on daily activities, the burden of an increased number of injections and worry about weight gain[8](#jdi12086-bib-0008 jdi12086-bib-0025){ref-type="ref"}. Most studies of QOL in relation to insulin treatment have focused on comparisons between human insulin or insulin analog initiation, rather than the effect of changing insulin regimen. However, because of the progressive nature of type 2 diabetes mellitus, most patients will eventually need intensification of insulin therapy to maintain glycemic control. The present study is the first to examine the effects of a range of insulin regimen changes on these parameters in a clinical practice setting, and contributes much‐needed data that will help patients and doctors make informed treatment choices.

In the present large observational study, changes of insulin therapy improved glycemic control in Japanese patients with type 2 diabetes mellitus without adversely affecting QOL. Patients enrolled in the present study were relatively established diabetic patients with more than 16 years\' history of illness and more than 7 years of insulin treatment on average. Therefore, it was expected that the changes in insulin therapy were at the level of 'modification'. In fact, the majority of changes in insulin therapy were changes in the type of insulin, and only approximately 20 and 30% of patients changed the device and the number of injections, respectively. This would be the primary reason why the changes in insulin therapy did not significantly affect patients\' QOL.

Subpopulation analyses by type of regimen changes showed that the ITR‐QOL total score increased from baseline to week 12 in the subgroups of patients who changed the type of insulin, who did not change the type of injection device and who did not change the number of injections. The reason why changing the type of insulin contributed to improvements in a patients\' QOL was probably because physicians chose more appropriate insulin preparations for individual patients. Regarding the influence of changes of injection device or the number of injections, improvement in glycemic control might have helped sustain patients\' QOL despite any adverse emotional impact arising from regimen changes, as it was shown that better glycemic control was clearly related to better QOL in insulin therapy[17](#jdi12086-bib-0017){ref-type="ref"}. Thus, doctors can reassure patients that modifying their insulin therapy is unlikely to detract from their QOL.

Interestingly, 'doctor recommendation' was the main patient‐reported reason for changing insulin regimen, suggesting that patients might not fully understand the clinical reasons for changing their regimen. Similar findings were reported in a substudy of the Treating to Target in Type 2 Diabetes trial, in which patients who required intensification of insulin therapy were willing to do so when recommended by their doctor[26](#jdi12086-bib-0026){ref-type="ref"}. Because patients who understand the reasons for changes in therapy are more motivated to adhere to treatment[27](#jdi12086-bib-0027){ref-type="ref"}, doctors should openly discuss potential changes in insulin regimen to ensure patients are actively involved in the decision.

The results of the present study are strengthened by the large number of patients from 68 medical centers. The present study provides an important 'snapshot' of the current pattern of insulin use among Japanese patients with type 2 diabetes mellitus. The patients in the present study used a wide range of insulin types, and no single type predominated. In Japan, biphasic insulin was used as frequently as rapid‐acting and long‐acting insulin. This is in contrast to Western countries, where guidelines from the American Diabetes Association and the European Association for the Study of Diabetes recommend long‐acting basal insulin for insulin initiation[28](#jdi12086-bib-0028){ref-type="ref"}. This difference in insulin type might be because intrinsic insulin secretion after meals is more impaired in patients from Japan than in patients from Western countries[29](#jdi12086-bib-0029 jdi12086-bib-0030){ref-type="ref"}.

The present study had several limitations. As expected in an observational study, there was considerable heterogeneity in both the study population and insulin regimens. However, the intention of the study was to examine 'real‐life' clinical practice in a broad range of patients with type 2 diabetes mellitus in Japan. Because the study did not include a control group, the observed improvement in glycemic control cannot be ascribed directly to the change in insulin regimen, as other factors (e.g. changes in lifestyle) might have contributed. One limitation of the QOL scales we used was the difficulty in detecting improvements if the initial ratings were relatively high (i.e. 'ceiling effect')[10](#jdi12086-bib-0010){ref-type="ref"}. We also cannot exclude the possibility that participation in the study itself might have affected patients\' perception of QOL. Finally, because of the limited duration of the study, we do not know how long QOL and glycemic control are maintained during treatment with the new insulin regimen or whether they are maintained after subsequent regimen changes.

In conclusion, it was suggested that changes in insulin regimen might improve glycemic control in patients with type 2 diabetes mellitus without detracting from QOL. The range of insulin types currently available in Japan allows doctors\' flexibility in tailoring insulin therapy to optimize both the clinical and QOL needs of individual patients. This is the first publication for the INSIGHTs observational study focusing on the whole study population. Further subgroup analysis by various aspects might provide additional information regarding glycemic control and patients\' QOL.
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